↓ Skip to main content

EGF816 exerts anticancer effects in non-small cell lung cancer by irreversibly and selectively targeting primary and acquired activating mutations in the EGF receptor

Overview of attention for article published in Cancer Research, January 2016
Altmetric Badge

About this Attention Score

  • In the top 5% of all research outputs scored by Altmetric
  • One of the highest-scoring outputs from this source (#8 of 7,070)
  • High Attention Score compared to outputs of the same age (99th percentile)
  • High Attention Score compared to outputs of the same age and source (99th percentile)

Mentioned by

news
67 news outlets
twitter
2 tweeters
reddit
1 Redditor

Citations

dimensions_citation
69 Dimensions

Readers on

mendeley
51 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
EGF816 exerts anticancer effects in non-small cell lung cancer by irreversibly and selectively targeting primary and acquired activating mutations in the EGF receptor
Published in
Cancer Research, January 2016
DOI 10.1158/0008-5472.can-15-2581
Pubmed ID
Authors

Yong Jia, Jose Juarez, Jie Li, Mari Manuia, Matthew J. Niederst, Celin Tompkins, Noelito Timple, Mei-Ting Vaillancourt, AnneMarie Culazzo Pferdekamper, Elizabeth L. Lockerman, Chun Li, Jennifer Anderson, Carlotta Costa, Debbie Liao, Eric Murphy, Michael DiDonato, Badry Bursulaya, Gerald Lelais, Jordi Barretina, Matthew McNeill, Robert Epple, Thomas H. Marsilje, Nuzhat Pathan, Jeffrey A. Engelman, Pierre-Yves Michellys, Peter McNamara, Jennifer Harris, Steven Bender, Shailaja Kasibhatla, Jia, Yong, Juarez, Jose, Li, Jie, Manuia, Mari, Niederst, Matthew J, Tompkins, Celin, Timple, Noelito, Vaillancourt, Mei-Ting, Culazzo Pferdekamper, AnneMarie, Lockerman, Elizabeth L, Li, Chun, Anderson, Jennifer, Costa, Carlotta, Liao, Debbie, Murphy, Eric, DiDonato, Michael, Bursulaya, Badry, Lelais, Gerald, Barretina, Jordi, McNeill, Matthew, Epple, Robert, Marsilje, Thomas H, Pathan, Nuzhat, Engelman, Jeffrey A, Michellys, Pierre-Yves, McNamara, Peter, Harris, Jennifer, Bender, Steven, Kasibhatla, Shailaja

Abstract

Non-small cell lung cancer (NSCLC) patients carrying oncogenic EGFR mutations initially respond to EGFR-targeted therapy, but later elicit minimal response due to dose-limiting toxicities and acquired resistance. EGF816 is a novel, irreversible mutant-selective EGFR inhibitor that specifically targets EGFR activating mutations arising de novo and upon resistance acquisition, while sparing wild-type (WT) EGFR. EGF816 potently inhibited the most common EGFR mutations L858R, Ex19del, and T790M in vitro, which translated into strong tumor regressions in vivo in several patient-derived xenograft models. Notably, EGF816 also demonstrated antitumor activity in an exon 20 insertion mutant model. At levels above efficacious doses, EGF816 treatment led to minimal inhibition of WT EGFR, and was well-tolerated. In single dose studies, EGF816 provided sustained inhibition of EGFR phosphorylation, consistent with its ability for irreversible binding. Furthermore, combined treatment with EGF816 and INC280, a cMET inhibitor, resulted in durable antitumor efficacy in a xenograft model that initially developed resistance to first-generation EGFR inhibitors via cMET activation. Thus, we report the first pre-clinical characterization of EGF816, and provide the groundwork for its current evaluation in Phase I/II clinical trials in patients harboring EGFR mutations, including T790M.

Twitter Demographics

The data shown below were collected from the profiles of 2 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 51 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 51 100%

Demographic breakdown

Readers by professional status Count As %
Researcher 16 31%
Other 8 16%
Student > Master 7 14%
Student > Bachelor 5 10%
Student > Ph. D. Student 4 8%
Other 6 12%
Unknown 5 10%
Readers by discipline Count As %
Biochemistry, Genetics and Molecular Biology 13 25%
Chemistry 10 20%
Medicine and Dentistry 8 16%
Agricultural and Biological Sciences 6 12%
Pharmacology, Toxicology and Pharmaceutical Science 4 8%
Other 4 8%
Unknown 6 12%

Attention Score in Context

This research output has an Altmetric Attention Score of 524. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 10 May 2016.
All research outputs
#6,197
of 7,679,268 outputs
Outputs from Cancer Research
#8
of 7,070 outputs
Outputs of similar age
#527
of 327,074 outputs
Outputs of similar age from Cancer Research
#4
of 447 outputs
Altmetric has tracked 7,679,268 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 99th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 7,070 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 6.7. This one has done particularly well, scoring higher than 99% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 327,074 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 99% of its contemporaries.
We're also able to compare this research output to 447 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 99% of its contemporaries.